The median follow-up time was 17.6 months ; the median progression free survival ( PFS ) was 10.7 ( 95 % CI 7.0-14 .4 ) months ; and the estimated median overall survival ( OS ) time was 33.0 ( 95 % CI 8.7-57 .3 ) months .